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Abstract: Background: Sentinel	 lymph	node	biopsy	 in	 thin	 invasive	primary	cutaneous	melanoma	(up	 to	1mm	thick)	 is	a	
controversial	subject.	The	presence	of	 tumor-infiltrating	 lymphocytes	could	be	a	 factor	 to	be	considered	 in	 the	decision	to	
perform this procedure. 
oBjective: To	evaluate	the	association	between	the	presence	of	 tumor-infiltrating	lymphocytes	and	lymph	node	metastases	
caused by thin primary cutaneous melanoma. 
Methods: Cross-sectional study with 137 records of thin invasive primary cutaneous melanoma submitted to sentinel 
lymph	node	biopsy	 from	2003	 to	2015.	The	clinical	variables	 considered	were	age,	 sex	and	 topography	of	 the	 lesion.	The	
histopathological	 variables	 assessed	 were:	 tumor-infiltrating	 lymphocytes,	 melanoma	 subtype,	 Breslow	 thickness,	 Clark	
levels,	number	of	mitoses	per	mm²,	ulceration,	regression	and	satellitosis.	Univariate	analyzes	and	logistic	regression	tests	
were performed as well the odds ratio and statistical relevance was considered when p <0.05. 
results: Among	the	137	cases	of	thin	primary	cutaneous	melanoma	submitted	to	sentinel	lymph	node	biopsy,	10	(7.3%)	had	
metastatic	involvement.	Ulceration	on	histopathology	was	positively	associated	with	the	presence	of	metastatic	lymph	node,	
with	odds	 ratio	=12.8	 (2.77-59.4	95%	CI,	p=0.001).	The	presence	of	moderate/marked	 tumor-infiltrating	 lymphocytes	was	
shown	to	be	a	protective	factor	for	the	presence	of	metastatic	lymph	node,	with	OR=0.20	(0.05-0.72	95%	CI,	p=0.014).	The	other	
variables - clinical and histopathological - were not associated with the outcome. 
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INTRODUCTION
Early diagnosis of melanoma is a vital necessity in view of 
the reduced survival with the progression of the disease. In invasive 
early	lesions,	i.e.,	up	to	1mm	thickness	and	not	in situ,	lymph	node	
involvement is one of the main prognostic factors.1,2	Thus,	tumors	
classified	as	T1	(≤	1mm	thick)	by	the	American	Joint	Committee	on	
Cancer	 (AJCC),	 despite	 representing	 the	 majority	 of	 melanomas	
(63%),	can	belong	to	clinical	stage	III	(due	to	lymph	node	involve-
ment)	and	patients	have	their	5-year	survival	significantly	reduced	
(98.9%	 for	 T1a	 and	 93.7%	 for	 T1b)	 to	 53.7%.3,4 This explains the 
fact that thin melanomas being responsible for up to 25% of death 
caused by this disease.3
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The recommendation for sentinel lymph node biopsy 
(SLNB)	 in	 a	 thin	 cutaneous	 melanoma	 (≤	 1mm)	 is	 controversial,	
since some authors consider the chance of lymph node involvement 
to	be	 low	 in	 this	group,	particularly	when	 the	 thickness	 is	of	 less	
than 0.75mm.5-10	On	the	other	hand,	some	authors	present	data	that	
add	to	the	existing	doubts	on	the	subject.	Fearfield	et al. 11 found 2 
to	18%	of	 recurrence	 in	up	 to	11	years	when	melanoma	 thickness	




Tumor-infiltrating	 lymphocytes	 (TIL)	 play	 a	 central	 role	
in targeted-therapy revolution.13-15 Its understanding triggered ad-
vances in immunotherapy and their presence represents a favorable 




of	another	 level	 in	 lymphocytic	activity,	with	standardization	into	
few,	moderate	and	marked.	This	new	sub-classification	was	used	in	
the study by Fortes.18,19
The	main	objective	of	this	study	was	to	investigate	the	re-
lationship between metastatic involvement of sentinel lymph node 
and	 the	presence	and	 intensity	of	 tumor-infiltrating	 lymphocytes.	
The	secondary	objectives	were	 to	compare	 the	other	clinical	char-
acteristics and pathological microstaging with the same outcome.
METHODS
Cross-sectional study conducted with data registered be-
tween	2003	and	2015	in	the	Laboratory	of	Pathology,	Santa	Casa	de	
Porto	Alegre,	 an	oncology	 reference	 center	 in	 the	 south	of	Brazil.	
Cases	 with	 invasive	 lesions	 ≤1mm,	 with	 no	 clinical	 lymph	 node	
involvement,	submitted	to	SLNB	were	eligible.	Clinical	and	histo-
logical	variables	were	assessed:	age,	sex,	topography	of	the	lesion,	
histological	 subtype,	 presence	 of	 TIL	 (graded	 into	 few,	moderate	
and	marked),	Breslow	 thickness,	Clark	 levels,	mitoses,	ulceration,	
regression and satellitosis. The study was approved by the commit-
tee of ethics in research of the institution under the number 653.823. 
After	the	diagnosis	of	melanoma	with	excisional	biopsy,	the	
patients were submitted to staging with clinical examination and 
imaging	 studies.	 In	 the	 immediate	 pre-operative	 period,	 the	 pa-
tients were reassessed and only those cases with no lymph node 
involvement	were	included	in	the	study,	ruling	out	the	possibility	
of over-indicating SLNB in view of an already existing indication 
for	lymphadenectomy.	All	SLNB	negative	on	examination	with	he-
matoxylin	&	 eosin	were	 submitted	 to	 immunohistochemistry.	All	
patients diagnosed with secondary implants in the sentinel lymph 
nodes were submitted to lymphadenectomy.
For	the	statistical	analysis,	the	level	of	significance	adopted	
was	 5%	 (p<0.05)	 and	 the	 analyses	were	made	using	 the	program	
SPSS version 21.0. The main outcome was metastatic involvement of 
the sentinel lymph node. The Odds Ratio	(OR),	together	with	the	95%	
confidence	interval,	was	calculated	to	estimate	the	effect	of	each	fac-
tor on the main outcome. The ROC (Receiver Operating Characteristic)	
curve was evaluated to estimate the best cut-off point for Breslow 
thickness	according	to	sentinel	lymph	node	positivity	and	the	area	
on the curve was calculated to estimate the accuracy of this score for 
predicting the outcome. Student’s T test was used for the compari-
son of the means between patients with and without sentinel lymph 
node	 involvement.	 In	 case	 of	 asymmetry,	 the	Mann-Whitney	 test	
was	used.	Fisher’s	exact	test	or	Pearson’s	chi-square	test	(variables	
with	more	than	two	categories)	were	used	in	the	comparison	of	pro-






One hundred and thirty-seven cases of TPCM that had pro-
tocol indication for the procedure were submitted to SNLB (pres-
ence	of	ulceration,	mitosis,	thickness	more	than	0.75mm,	regression),	
among	which	10	 (7.3%)	had	metastatic	 lymph	node	 involvement.	
After	multivariate	regression	analysis,	only	two	factors	had	statis-
tical	 significance.	 The	 group	 that	 had	moderate	 and	marked	 TIL	
showed	a	reduction	in	the	risk	of	sentinel	lymph	node	involvement,	
with	OR=0.2	 (95%	CI:	 0.02–0.72	 and	p=0.014),	 and	 those	with	ul-
ceration	had	a	12.8-fold	higher	risk	of	lymph	node	metastatization:	
OR=12.8	(95%	CI:	2.77–59.4	and	p=0.001);	these	findings	are	shown	







tuting an exception case.
The	 ROC	 curve	 demonstrated	 a	 non-statistically	 signifi-
cant	(p=0.282)	tendency	that	thickness	≥0.79mm	would	increase	the	
chance of sentinel lymph node positivity. 
The	 lowest	Breslow	 thickness	associated	 to	positive	 senti-
nel	lymph	node	was	0.31mm.	In	4	cases	(40%),	the	identification	of	
metastasis in sentinel lymph node was only possible with immuno-
histochemistry.	Among	the	patients	who	were	submitted	to	lymph	
node	resection,	there	was	metastatization	to	other	lymph	nodes	in	
50% of the lymph nodes detected with immunohistochemistry. For 
the	sentinel	lymph	nodes	positive	on	hematoxylin	&	eosin,	lymph-
adenectomy found other implants in 66% of cases. The mean num-
ber of resected lymph nodes was 27.5.
DISCUSSION
In	the	present	study,	the	presence	of	moderate/marked	TIL	
was a protection factor for the presence of metastatic lymph node. 
Patients	 with	 moderate/marked	 TIL	 in	 the	 primary	 melanoma	
lesion	 had	 a	 five-fold	 lower	 risk	 for	 the	 presence	 of	 one	 positive	
lymph node when compared to individuals with absent or few TIL 
in the lesion. 
An	 increasing	number	 of	 studies	 show	 that	 the	 individu-
al immune response related to TIL can yield consistent results re-
garding	improved	survival,	defining	TIL	as	a	prognostic	factor.18-22 
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Table 1: Overall characteristics of the sample: patients with thin primary cutaneous melanomas and metastatic sentinel lymph node 
involvement (2003-2015, Laboratory of Pathology, Santa Casa de Porto Alegre, Brazil); n= 137
SLN involvement
Variables Yes (n=10; 7.3%) No (n=127; 92.7%) P*
Age	(years) 52.1 ± 12.5 53.9 ± 13.4 0.682
Sex	–	n	(%) - - 0.104
 Male 7	(70.0) 53	(41.7) -
 Female 3	(30.0) 74	(58.3) -
Location – n (%) 0.533
 Lower limbs 0	(0.0) 22	(17.3) -
	 Trunk 6	(60.0) 61	(48.0) -
	 Head	and	neck 2	(20.0) 10	(7.9) -
 Upper limbs 2	(20.0) 27	(21.3) -
	 Vulva 0	(0.0) 1	(0.8) -
	 Acral 0	(0.0) 6	(4.7) -
Type – n (%) 0.567
	 Superficial	spreading 9	(90.0) 113	(89.0) -
 Lentigo 0	(0.0) 8	(6.3) -
 Nodular 1	(10.0) 6	(4.7) -
Clark – n (%) 0.005
 I 0	(0.0) 1	(0.8) -
 II 1	(10.0) 44	(34.6) -
 III 5	(50.0) 52	(40.9) -
	 IV 3	(30.0) 30	(23.6) -
	 V 1	(10.0) 0	(0.0) -
Breslow – mean ± SD 0.68 ± 0.26 0.65 ± 0.24 0.635
	 <0,76 5	(50.0) 76	(59.8) 0.740
	 ≥0,76 5	(50.0) 51	(40.2) -
Intensity of TIL – n (%) 0.080
 Negative 1	(10.0) 3	(2.4) -
 Few 6	(60.0) 39	(30.7) -
 Moderate 3	(30.0) 63	(49.6) -
	 Marked	 0	(0.0) 22	(17.3) -
Location TIL – n (%) 0.512
 Peritumoral 6/9	(66.7) 67/124	(54.0) -
 Peritumoral and intratumoral 3/9	(33.3) 57/124	(46.0) -
Regression – n (%) 0.096
 Positive 3	(30.0) 76	(59.8) -
 Negative 7	(70.0) 51	(40.2) -
Ulceration – n (%) 0.141
 Positive 1	(10.0) 1	(0.8) -
 Negative 9	(90.0) 126	(99.2) -
Satellitosis – n (%) 0.505
 Positive 1	(10.0) 8	(6.3) -
 Negative 9	(90.0) 119	(93.7) -
Mitoses – n (%) 0.686
 Positive 9	(90.0) 101	(79.5) -
 Negative 1	(10.0) 26	(20.5) -
*Statistical	tests	used:	Student,	Mann-Whitney,	Fisher’s	exact,	Pearson’s	chi-square
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Table 2: Multivariate analysis* to evaluate independent 
factors associated to sentinel lymph node involvement in 
thin primary cutaneous melanomas (2003-2015, Laboratory of 
Pathology, Santa Casa de Porto Alegre, Brazil); n= 137


















However,	 the	use	of	 this	 information	 in	 the	early	management	of	
TPCM is limited. In the studies by Burton et al.23 and Duprat et al.24,	
the active presence of TIL demonstrated sentinel lymph node pro-
tection	in	melanomas	thicker	than	1mm.	In	the	studies	by	Fortes	et 
al.19,	Mandala	et al.25 and Taylor et al.26,	TPCM	were	included	with	
the	 thicker	melanomas	and	 the	group	demonstrated	a	higher	risk	
for	 SLNB	positivity	when	TIL	was	 absent	 or	 few/inactive.	Azimi	
presented similar results to those authors but the analysis was of 





It is extremely important to consider that local control of 
the disease in patients with lymph node involvement can improve 
disease- and recurrence-free survival when done early (SNLB fol-
lowed	by	 lymphadenectomy),	with	better	 local	 control	of	 the	dis-
ease	 (avoiding	 lymph	node	 tumor	masses,	many	times	associated	
to	ulceration,	infection	and	bleeding,	situations	of	difficult	clinical	
management	 and	 great	 suffering	 for	 the	 patient),	 despite	 not	 im-
proving overall.28-35
As	 limitation	 of	 the	 study,	 the	 coherence	with	 studies	 by	
Azimi	et al.18 and Fortes et al.19	in	the	characterization	of	ulceration	as	
a	risk	factor	for	sentinel	lymph	node	should	be	evaluated	carefully,	
because	even	by	demonstrating	a	significantly	high	risk	(12.8-fold),	
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